Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030305 (
pancreatitis
)
16,014
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study examined the expression of cell adhesion molecule 1 (CADM1) in pancreatic cancer and the possible mechanism. The expression of CADM1 was detected by immunohistochemistry in tissues of pancreatic cancer,
pancreatitis
, and normal pancreas. The plasmid pcDNA3.1-Hygro(+)/CADM1 was transfected into PANC-1 cells (a pancreatic cancer cell line). The expression of CADM1 in the transfected cells was determined by RT-PCR and Western blotting. Cell growth was measured by the MTT method and cell apoptosis by flow cytometry. The results showed that CADM1 was weakly expressed in tissues of pancreatic cancer in contrast to its high expression in normal pancreatic and
pancreatitis
tissues. The expression level of CADM in pancreatic caner was intensely correlated with the differentiation degree, lymph node metastasis and
TNM
stages. The growth of CADM1-transfected PANC-1 cells was significantly suppressed in vitro by a G1 cell cycle arrest and apoptosis occurrence. It was concluded that re-expression of CADM1 inhibits the growth of pancreatic cancer cells and induces their apoptosis in vitro. As a tumor suppressor gene, CADM1 plays an important role in the occurrence, progression and metastasis of pancreatic cancer.
...
PMID:Re-expression of cell adhesion molecule inhibits growth and induces apoptosis of human pancreatic cancer cell line PANC-1. 2217 95
Purpose:
Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer and early detection and accurate staging are critical to prolonging survival. PDAC typically has a prominent stroma including cancer-associated fibroblasts (CAFs) that express Fibroblast Activation Protein (FAP). FAP is a new target molecule for PET imaging of various tumors. In this retrospective study we describe the clinical impact of PET/CT imaging using
68
Ga-labelled FAP-Inhibitors (
68
Ga-FAPI - PET/CT) in 19 patients with PDAC (7 primary, 12 progressive/recurrent).
Patients and Methods:
All patients have undergone contrast enhanced Computed Tomography (ceCT) for
TNM
staging before they were subjected to
68
Ga-FAPI - PET/CT imaging. PET-scans were acquired 60 minutes after administration of 150-250 MBq of
68
Ga-labelled FAP-specific tracers. In order to characterize
68
Ga-FAPI-uptake over time, additional scans after 10 minutes and/or 180 minutes were performed in six patients. SUV
max
and SUVmean values of PDAC manifestations and healthy organs were analyzed. The tumor burden according to
68
Ga-FAPI - PET/CT was compared to
TNM
staging based on ceCT and changes in oncological management were recorded.
Results:
Compared to ceCT,
68
Ga-FAPI - PET/CT results led to changes in
TNM
staging in 10/19 patients. 8/12 patients with recurrent/progressive disease, were up-staged, 1 down-staged and 3 had no change. In newly diagnosed PDAC, 1/7 patients was up-staged, the staging of 6 patients did not change. Changes in oncological management occurred in seven patients. Markedly elevated uptake of
68
Ga-FAPI in PDAC manifestations after 1 hour was seen in most cases. Differentiation from
pancreatitis
based on static imaging 1 hour p.i. was challenging. With respect to imaging after multiple time points, PDAC and
pancreatitis
showed a trend for differential uptake kinetics.
Conclusion:
68
Ga-FAPI - PET/CT led to restaging in half of patients with PDAC and most patients with recurrent disease compared to standard of care imaging. The clinical value of
68
Ga-FAPI - PET/CT should be further investigated.
...
PMID:Impact of
68
Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. 3309 32
